Literature DB >> 7504473

Altered ligand specificity of proteolysed insulin-like growth factor binding protein-3.

R C Baxter1, L Skriver.   

Abstract

IGF binding protein-3 (IGFBP-3) undergoes limited proteolysis in human pregnancy serum, altering its electrophoretic mobility and its binding of radioiodinated IGF tracers. IGF-I tracer, monoiodinated on Tyr31, discriminated less than other tracers between intact and proteolysed IGFBP-3. In competitive binding curves using this tracer, intact IGFBP-3 showed comparable reactivity towards IGF-I and analogs with substitutions at Tyr24, Tyr31 or Tyr60. In contrast, proteolysed IGFBP-3 reacted equally with IGF-I and [Ala31]IGF-I (approximately 10-fold lower potency than with intact IGFBP-3), but showed a marked selectivity against [Ser24]IGF-I and [Leu60]IGF-I (approximately 100-fold lower potency than with intact IGFBP-3). The affinity of IGF-I binding to proteolysed, but not intact, IGFBP-3 was increased by the addition of the acid-labile subunit of the IGFBP-3 complex. This study defines more fully the lesion in IGFBP-3 caused by serum proteolysis during pregnancy and demonstrates that tyrosine-substituted IGF-I derivatives are valuable tools in studying IGFBP-3 proteolysis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504473     DOI: 10.1006/bbrc.1993.2389

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Damage control mechanisms in articular cartilage: the role of the insulin-like growth factor I axis.

Authors:  J A Martin; M B Scherb; L A Lembke; J A Buckwalter
Journal:  Iowa Orthop J       Date:  2000

2.  Postsynthetic regulation of insulin-like growth factor-binding protein-3 by MCF-7 human breast cancer cells in culture.

Authors:  R W Grimes; A Manni; J M Hammond
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose.

Authors:  Qiuhua Zhang; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-30       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.